- Conditions
- Parathyroid Adenoma
- Interventions
- 18Fluorocholine
- Drug
- Lead sponsor
- Andrei Iagaru
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Stanford, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 97–120
of 281
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Secondary Hyperparathyroidism, End-stage Kidney Disease (ESKD)
- Interventions
- PLS240, Placebo, Open-Label Extension PLS240
- Drug
- Lead sponsor
- Pathalys Pharma
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 362 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 49
- States / cities
- Pine Bluff, Arkansas • Anaheim, California • Beverly Hills, California + 41 more
- Conditions
- Locally Advanced Adrenal Gland Pheochromocytoma, Locally Advanced Paraganglioma, Metastatic Adrenal Gland Pheochromocytoma, Metastatic Paraganglioma, Metastatic Parathyroid Gland Carcinoma, Pituitary Gland Carcinoma, Somatostatin Receptor Positive, Stage III Thyroid Gland Medullary Carcinoma AJCC v8, Stage IV Thyroid Gland Medullary Carcinoma AJCC v8, Stage IVA Thyroid Gland Medullary Carcinoma AJCC v8, Stage IVB Thyroid Gland Medullary Carcinoma AJCC v8, Stage IVC Thyroid Gland Medullary Carcinoma AJCC v8, Unresectable Adrenal Gland Pheochromocytoma, Unresectable Paraganglioma
- Interventions
- Lutetium Lu 177 Dotatate
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Parathyroid Dysfunction, Adenoma
- Interventions
- Indocyanine green, SPY Portable Handheld Imaging
- Drug · Device
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 417 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Secondary Hyperparathyroidism, End Stage Kidney Disease
- Interventions
- PLS240, Placebo, Open-Label Extension PLS240
- Drug
- Lead sponsor
- Pathalys Pharma
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 412 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 50
- States / cities
- Anaheim, California • Chula Vista, California • Escondido, California + 43 more
- Conditions
- Hyperparathyroidism, Secondary
- Interventions
- Etelcalcetide, Placebo
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 508 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 51
- States / cities
- Birmingham, Alabama • Pine Bluff, Arkansas • Azusa, California + 44 more
- Conditions
- Hypoparathyroidism
- Interventions
- NPSP558
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 12
- States / cities
- Lakewood, California • Chicago, Illinois • Indianapolis, Indiana + 9 more
- Conditions
- Primary Hyperparathyroidism, Hypercalcemia
- Interventions
- Calcitonin
- Drug
- Lead sponsor
- Joseph Sferra
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 1
- States / cities
- Toledo, Ohio
- Conditions
- Endocrine Disease
- Interventions
- Data Collection, Follow Up
- Other · Behavioral
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 15,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Parathyroid Disease
- Interventions
- FACBC
- Drug
- Lead sponsor
- David M. Schuster, MD
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Hyperthyroidism
- Interventions
- Not listed
- Lead sponsor
- Walter Reed Army Medical Center
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2012
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Postmenopausal Osteoporosis
- Interventions
- abaloparatide, abaloparatide solid microstructured transdermal system
- Combination Product
- Lead sponsor
- Radius Health, Inc.
- Industry
- Eligibility
- 50 Years to 85 Years · Female only
- Enrollment
- 511 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 77
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Glendale, Arizona + 65 more
- Conditions
- Osteoporosis
- Interventions
- teriparatide
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- Not listed
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 18
- States / cities
- Huntsville, Alabama • Montgomery, Alabama • Peoria, Arizona + 15 more
- Conditions
- Hypoparathyroidism
- Interventions
- PTH
- Drug
- Lead sponsor
- John P. Bilezikian
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2014
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Chronic Kidney Disease, Secondary Hyperparathyroidism, Chronic Renal Insufficiency, Chronic Renal Failure
- Interventions
- CTAP201 Injection, Doxercalciferol
- Drug
- Lead sponsor
- OPKO IP Holdings II, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 6
- States / cities
- Peoria, Arizona • Springfield, Massachusetts • Cincinnati, Ohio + 3 more
- Conditions
- Osteoporosis, Postmenopausal
- Interventions
- teriparatide, raloxifene HCl, placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 55 Years to 80 Years · Female only
- Enrollment
- 330 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2005
- U.S. locations
- 2
- States / cities
- Maywood, Illinois • Portland, Oregon
- Conditions
- Hyperparathyroidism
- Interventions
- Vitamin D, Four-dimensional computed tomography (4DCT)
- Drug · Device
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2018
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Hypoparathyroidism
- Interventions
- Placebo, NPSP558
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 19
- States / cities
- Scottsdale, Arizona • Lakewood, California • Orange, California + 16 more
- Conditions
- Renal Failure
- Interventions
- calcium acetate, aluminum hydroxide, Sevelamer
- Drug
- Lead sponsor
- National Center for Research Resources (NCRR)
- NIH
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Hypoparathyroidism, Endocrine System Diseases, Parathyroid Diseases
- Interventions
- TransCon PTH, Placebo for TransCon PTH
- Combination Product
- Lead sponsor
- Ascendis Pharma A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 5
- States / cities
- Chicago, Illinois • Rochester, Minnesota • Great Neck, New York + 2 more
- Conditions
- Osteoporosis
- Interventions
- Teriparatide
- Drug
- Lead sponsor
- Pfenex, Inc
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Evansville, Indiana
- Conditions
- Kidney Disease
- Interventions
- Vitamin D, Placebo
- Dietary Supplement · Other
- Lead sponsor
- Atlanta VA Medical Center
- Federal
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Parathyroid Disease
- Interventions
- Not listed
- Lead sponsor
- University of Arkansas
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2022
- U.S. locations
- 1
- States / cities
- Little Rock, Arkansas
- Conditions
- Chronic Kidney Disease, Kidney Transplantation
- Interventions
- Doxercalciferol, placebo, 25-OH Vitamin D3
- Drug
- Lead sponsor
- Mariana Markell
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Brooklyn, New York